organization · Reporting owner
5AM Ventures VII, L.P.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Skye Bioscience, Inc.SKYE · Entity 8098 | 10% owner | September 22, 2026 | September 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Skye Bioscience, Inc.
Report date September 22, 2026 · Filed September 24, 2026
Jointly reported with 5AM Partners VII, LLC, 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, PARMAR KUSH, ROCKLAGE SCOTT M
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy 5AM Ventures II, L.P. | 0 |
Last balance in matching sequence
After 2026-09-23 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-09-22 · Sale · Disposed 27,612 · Balance 114,851 F1: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Row 3 · 2026-09-23 · Sale · Disposed 114,851 · Balance 0 F3: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F1: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectBy 5AM Co-Investors II, L.P. | 0 |
Last balance in matching sequence
After 2026-09-23 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2026-09-22 · Sale · Disposed 1,088 · Balance 4,528 F2: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Row 4 · 2026-09-23 · Sale · Disposed 4,528 · Balance 0 F3: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectBy 5AM Ventures VII, L.P. | 981,269 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 981,269 F4: The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
F2: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
F3: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F4: The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Camp4 Therapeutics Corp
Report date August 03, 2026 · Filed August 05, 2026
Jointly reported with 5AM Partners VI, LLC, 5AM Ventures VI, L.P., 5AM Opportunities II (GP), LLC, 5AM Opportunities II, L.P., 5AM Partners VII, LLC, PARMAR KUSH
Section 16 reporting ended · disclosed 2026-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Pre-Funded Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy 5AM Ventures VII, L.P. | 3,179,558 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Purchase · Acquired 3,179,558 · Balance 3,179,558 F1: The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, 5AM Ventures VII, L.P. ("Ventures VII") shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by Ventures VII, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise. F2: The shares are directly held by Ventures VII. 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. |
Filing footnotes · ownership attribution and instrument terms
F1: The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, 5AM Ventures VII, L.P. ("Ventures VII") shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by Ventures VII, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.
F2: The shares are directly held by Ventures VII. 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2026 Filed Sep 24, 2026 20:29 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 4,528 | $1.61 | $7,290.08 |
DisclosureSEC source: 0001231919-26-001224 · form4-09242026_080923.xml · nonDerivative · entry 4 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Co-Investors II, L.P. Disclosed balance after: 0 F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| September 23, 2026 Filed Sep 24, 2026 20:29 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 114,851 | $1.61 | $184,910.11 |
DisclosureSEC source: 0001231919-26-001224 · form4-09242026_080923.xml · nonDerivative · entry 3 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures II, L.P. Disclosed balance after: 0 F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F1 · ownership.nature: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 20:29 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 1,088 | $1.65 | $1,795.20 |
DisclosureSEC source: 0001231919-26-001224 · form4-09242026_080923.xml · nonDerivative · entry 2 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Co-Investors II, L.P. Disclosed balance after: 4,528 F2 · ownership.nature: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 20:29 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 27,612 | $1.65 | $45,559.80 |
DisclosureSEC source: 0001231919-26-001224 · form4-09242026_080923.xml · nonDerivative · entry 1 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures II, L.P. Disclosed balance after: 114,851 F1 · ownership.nature: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 22:37 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 1,285 | $1.91 | $2,454.35 |
DisclosureSEC source: 0001231919-26-001197 · form4-09182026_100949.xml · nonDerivative · entry 2 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Co-Investors II, L.P. Disclosed balance after: 5,616 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 to $2.11 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 22:37 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 32,607 | $1.91 | $62,279.37 |
DisclosureSEC source: 0001231919-26-001197 · form4-09182026_100949.xml · nonDerivative · entry 1 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures II, L.P. Disclosed balance after: 142,463 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 to $2.11 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 20, 2026 Filed Aug 20, 2026 21:57 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 6,495 | $0.32 | $2,078.40 |
DisclosureSEC source: 0001231919-26-000959 · form4-08202026_090856.xml · nonDerivative · entry 9 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures VII, L.P. Disclosed balance after: 7,850,155 F4 · ownership.nature: The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 20, 2026 Filed Aug 20, 2026 21:57 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 46 | $0.32 | $14.72 |
DisclosureSEC source: 0001231919-26-000959 · form4-08202026_090856.xml · nonDerivative · entry 8 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Co-Investors II, L.P. Disclosed balance after: 55,208 F3 · ownership.nature: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 20, 2026 Filed Aug 20, 2026 21:57 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 1,159 | $0.32 | $370.88 |
DisclosureSEC source: 0001231919-26-000959 · form4-08202026_090856.xml · nonDerivative · entry 7 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures II, L.P. Disclosed balance after: 1,400,560 F2 · ownership.nature: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 21:57 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 57,476 | $0.35 | $20,116.60 |
DisclosureSEC source: 0001231919-26-000959 · form4-08202026_090856.xml · nonDerivative · entry 6 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures VII, L.P. Disclosed balance after: 7,856,650 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 21:57 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 409 | $0.35 | $143.15 |
DisclosureSEC source: 0001231919-26-000959 · form4-08202026_090856.xml · nonDerivative · entry 5 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Co-Investors II, L.P. Disclosed balance after: 55,254 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 21:57 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 10,255 | $0.35 | $3,589.25 |
DisclosureSEC source: 0001231919-26-000959 · form4-08202026_090856.xml · nonDerivative · entry 4 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures II, L.P. Disclosed balance after: 1,401,719 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 21:57 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 253,080 | $0.38 | $96,170.40 |
DisclosureSEC source: 0001231919-26-000959 · form4-08202026_090856.xml · nonDerivative · entry 3 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures VII, L.P. Disclosed balance after: 7,914,126 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 21:57 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 1,830 | $0.38 | $695.40 |
DisclosureSEC source: 0001231919-26-000959 · form4-08202026_090856.xml · nonDerivative · entry 2 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Co-Investors II, L.P. Disclosed balance after: 55,663 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 21:57 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 45,090 | $0.38 | $17,134.20 |
DisclosureSEC source: 0001231919-26-000959 · form4-08202026_090856.xml · nonDerivative · entry 1 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures II, L.P. Disclosed balance after: 1,411,974 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 21:39 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchasePre-Funded Warrant (Right to Buy) · Derivative | 3,179,558 | $1.53 Strike: $0.00 | $4,864,405.78 |
DisclosureSEC source: 0001231919-26-000829 · form4-08052026_090822.xml · derivative · entry 1 5AM Partners VI, LLC · CIK 0001829051 · 10% owner 5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner 5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner 5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures VII, L.P. Disclosed balance after: 3,179,558 Underlying: Common Stock · 3,179,558 shares Expires not disclosed F1 · derivative.exercise_date: The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, 5AM Ventures VII, L.P. ("Ventures VII") shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by Ventures VII, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise. F1 · derivative.expiration_date: The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, 5AM Ventures VII, L.P. ("Ventures VII") shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by Ventures VII, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise. F2 · ownership.nature: The shares are directly held by Ventures VII. 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| September 11, 2025 Filed Sep 16, 2025 00:12 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchaseCommon Stock | 2,941,176 | $1.53 | $4,499,999.28 |
DisclosureSEC source: 0001231919-25-000196 · form4-09152025_100930.xml · nonDerivative · entry 1 5AM Partners VI, LLC · CIK 0001829051 · 10% owner 5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner 5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner 5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures VII, L.P. Disclosed balance after: 2,941,176 F1 · ownership.nature: The shares are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 22, 2025 Filed Aug 22, 2025 23:05 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 6,470 | $3.42 | $22,127.40 |
DisclosureSEC source: 0001415889-25-022806 · form4-08222025_110831.xml · nonDerivative · entry 4 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Co-Investors II, L.P. Disclosed balance after: 57,493 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 22, 2025 Filed Aug 22, 2025 23:05 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 163,979 | $3.42 | $560,808.18 |
DisclosureSEC source: 0001415889-25-022806 · form4-08222025_110831.xml · nonDerivative · entry 3 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures II, L.P. Disclosed balance after: 1,457,064 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.59 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 21, 2025 Filed Aug 22, 2025 23:05 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 2,314 | $3.57 | $8,260.98 |
DisclosureSEC source: 0001415889-25-022806 · form4-08222025_110831.xml · nonDerivative · entry 2 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Co-Investors II, L.P. Disclosed balance after: 63,963 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 21, 2025 Filed Aug 22, 2025 23:05 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 58,642 | $3.57 | $209,351.94 |
DisclosureSEC source: 0001415889-25-022806 · form4-08222025_110831.xml · nonDerivative · entry 1 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures II, L.P. Disclosed balance after: 1,621,043 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.69 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| September 13, 2024 Filed Sep 13, 2024 22:54 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 79 | $6.06 | $478.74 |
DisclosureSEC source: 0001415889-24-023399 · form4-09132024_100903.xml · nonDerivative · entry 6 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Co-Investors II, L.P. Disclosed balance after: 66,277 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.05 to $6.11 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| September 13, 2024 Filed Sep 13, 2024 22:54 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 2,000 | $6.06 | $12,120.00 |
DisclosureSEC source: 0001415889-24-023399 · form4-09132024_100903.xml · nonDerivative · entry 5 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures II, L.P. Disclosed balance after: 1,679,685 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.05 to $6.11 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| September 13, 2024 Filed Sep 13, 2024 22:54 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 11,758 | $6.06 | $71,253.48 |
DisclosureSEC source: 0001415889-24-023399 · form4-09132024_100903.xml · nonDerivative · entry 4 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures VII, L.P. Disclosed balance after: 8,167,206 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.05 to $6.11 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.nature: The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 22:54 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 1,440 | $6.60 | $9,504.00 |
DisclosureSEC source: 0001415889-24-023399 · form4-09132024_100903.xml · nonDerivative · entry 3 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Co-Investors II, L.P. Disclosed balance after: 66,356 F3 · ownership.nature: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 22:54 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 36,504 | $6.60 | $240,926.40 |
DisclosureSEC source: 0001415889-24-023399 · form4-09132024_100903.xml · nonDerivative · entry 2 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures II, L.P. Disclosed balance after: 1,681,685 F2 · ownership.nature: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 22:54 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | SaleCommon Stock | 214,556 | $6.60 | $1,416,069.60 |
DisclosureSEC source: 0001415889-24-023399 · form4-09132024_100903.xml · nonDerivative · entry 1 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures VII, L.P. Disclosed balance after: 8,178,964 F1 · ownership.nature: The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 20:15 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | PurchaseCommon Stock | 450,000 | $10.00 | $4,500,000.00 |
DisclosureSEC source: 0001415889-24-008107 · form4-03152024_040305.xml · nonDerivative · entry 1 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures VII, L.P. Disclosed balance after: 8,393,520 F1 · ownership.nature: The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:32 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | PurchaseCommon Stock | 5,206,074 | $2.31 | $12,026,030.94 |
DisclosureSEC source: 0001209191-24-002643 · doc4.xml · nonDerivative · entry 1 5AM Partners VII, LLC · CIK 0001873545 · 10% owner 5AM Ventures VII, L.P. · CIK 0001844435 · 10% owner 5AM Partners II, LLC · CIK 0001555952 · 10% owner 5AM Ventures II LP · CIK 0001386509 · 10% owner 5AM CO-INVESTORS II LP · CIK 0001390376 · 10% owner DIEKMAN JOHN D · CIK 0001240357 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures VII, L.P. Disclosed balance after: 7,943,520 F1 · ownership.nature: The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.